Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome

Jeong Rae Yoo; Keun Hwa Lee; Misun Kim; Hyun Joo Oh; Sang Taek Heo

doi:10.1016/j.ijid.2022.06.058

Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome

Int J Infect Dis. 2022 Sep:122:656-658. doi: 10.1016/j.ijid.2022.06.058. Epub 2022 Jul 5.

Authors

Jeong Rae Yoo¹, Keun Hwa Lee², Misun Kim¹, Hyun Joo Oh¹, Sang Taek Heo³

Affiliations

¹ Department of Internal Medicine, Jeju National University, College of Medicine, Jeju, South Korea.
² Department of Microbiology, Hanyang University College of Medicine, Seoul, South Korea.
³ Department of Internal Medicine, Jeju National University, College of Medicine, Jeju, South Korea. Electronic address: neosangtaek@naver.com.

PMID: 35803471
DOI: 10.1016/j.ijid.2022.06.058

Abstract

We report the administration of an anti-interleukin (IL)-6 antibody in a case of severe fever with thrombocytopenia syndrome (SFTS) with an increase in IL-6. On the day of admission, SFTS viral load and IL-6 concentration were 93 831 copies/ml and 5.4 pg/ml, respectively, and tocilizumab was administered. SFTS viral load decreased to 17 821.1 copies/ml on the 3^rd day of admission, while IL-6 levels increased to 104.9 pg/ml; SFTS viral load and IL-6 levels had decreased to 2876.4 copies/ml and 48.2 pg/ml on 7^th day of admission, respectively. The patient fully recovered no tocilizumab adverse events.

Keywords: Dabie bandavirus; interleukin-6; severe fever with thrombocytopenia syndrome; tocilizumab.

Publication types

Case Reports

MeSH terms

Bunyaviridae Infections*
Fever / drug therapy
Humans
Interleukin-6
Phlebovirus*
Severe Fever with Thrombocytopenia Syndrome*
Thrombocytopenia* / drug therapy

Substances

Interleukin-6